Stay updated on Trametinib and Pembrolizumab in NSCLC Clinical Trial
Sign up to get notified when there's something new on the Trametinib and Pembrolizumab in NSCLC Clinical Trial page.

Latest updates to the Trametinib and Pembrolizumab in NSCLC Clinical Trial page
- Check4 days agoChange DetectedThe page now displays a 403 Forbidden error instead of the study details, replacing the previously visible trial information with an access-restricted error screen. This change indicates the trial record is currently unavailable due to an access issue.SummaryDifference19%

- Check12 days agoNo Change Detected
- Check18 days agoNo Change Detected
- Check26 days agoChange DetectedRevision tag updated from v3.6.5 to v3.6.6. This indicates a newer version of the page has been published, with no visible changes to the study content.SummaryDifference0.1%

- Check47 days agoChange DetectedThe page revision label changed from v3.6.4 to v3.6.5, indicating an updated publication version. This reflects a minor update to the page metadata rather than changes to the trial details or user-facing content.SummaryDifference0.1%

- Check61 days agoChange DetectedRevision v3.6.4 was added and Revision v3.6.3 was removed. This represents a minor update to the page's revision history.SummaryDifference0.1%

- Check68 days agoChange DetectedMid-July 2026 update timestamps were added to the study record and January 2026 timestamps were removed. This reflects a refresh of the record's revision history rather than changes to the study data.SummaryDifference0.2%

- Check83 days agoChange DetectedRevision tag updated from v3.6.2 to v3.6.3 on the page footer, signaling an updated version of the page content.SummaryDifference0.1%

Stay in the know with updates to Trametinib and Pembrolizumab in NSCLC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Trametinib and Pembrolizumab in NSCLC Clinical Trial page.